Skip To Main Content

Prurigo Nodularis Is A Distinct, Chronic, Neural And Immune- Mediated Skin Disease Characterized By Intense Itch And Nodular Lesions1

PN is characterized by the following:

  • Chronic pruritus1,2

    • Pruritus lasting ≥6 weeks is required for a diagnosis2
    • Most patients (>80%) have pruritus for >6 months and over half of patients
      experience pruritus for >2 years3
    • PN is regarded as having the highest itch intensity among the many diverse types
      of chronic pruritus4-6
    • The most burdensome symptom as rated by patients with PN is itch3,a
  • Presence of multiple, firm, pruriginous lesions1,2,b

    • Visibility of skin lesions and bleeding of skin lesions are the second and third most burdensome symptoms as rated by patients3,b
  • History and/or evidence of repeated scratching, picking, or rubbing (eg, excoriations and scars)2

PN negatively affects many aspects of patients’ quality of life, including7,8:

  • Sleep9,c

    • Pruritus is often worse in the evening or at night
    • Over 60% of patients with PN report that itching disturbs their sleep “to a great extent”
  • Mental health7,10,11

    • Patients with PN are more likely to have depression or anxiety compared with healthy individuals
  • Activities of daily living12,d

    • Over 50% of patients report that their everyday life is affected by PN
  • Social interactions12,d

    • 38% of patients report that itch affects their interactions with others

PN may be associated with the following comorbidities2,8:

  • Chronic conditions eg, Chronic kidney disease
  • Dermatological conditions eg, Atopic dermatitis
  • Infections eg, HIV
  • Psychiatric conditions eg, Depression

PN can arise as a distinct disease in the absence of any of the comorbidities above

The debilitating signs and symptoms of PN result in significantly reduced quality of life, including negatively impacting sleep, mental health, activities of daily living, and social interactions. In addition, PN may also be associated with a range of comorbidities8

MAT-BH-2200541/V1/June 2022